GeoVax收到了乙肝疫苗专利许可通知

StephenW

GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent

April 01, 2021 09:00 ET | Source: GeoVax, Inc.

    ...

Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide

Atlanta, GA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 16/305,305 entitled “Composition and Methods of Generating an Immune Response to Hepatitis B Virus.”

The work supporting the patent application was performed through a collaboration between GeoVax and Georgia State University and the patent is jointly owned by the Company and the Georgia State University Research Foundation (GSURF).

David Dodd, GeoVax’s Chairman & CEO, commented, “There is a clear, critical unmet medical need to treat chronic HBV infections, which affects over 250 million people worldwide. For many infected people, Hepatitis B has become a long-term, chronic infection that can lead to serious, or even life-threatening health issues like cirrhosis or liver cancer. Multiple vaccines exist to protect against HBV infection, but they cannot help patients already diagnosed with the disease. Although chronic HBV can be treated with drugs, the treatments do not cure 95% of patients, only suppressing the replication of the virus, forcing those who begin such treatments to continue with them for the rest of their lives.

“While our corporate focus and development priorities continue to be our COVID-19 vaccine and cancer immunotherapy programs, developing a treatment for chronic Hepatitis B infections is also of interest and under consideration as part of our longer-term focus.  This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families,” concluded Mr. Dodd.

“This project is a good example of how the combined expertise and talent of academic researchers and industry partners can solve problems, innovate, and create value,” added Clifford Michaels, Ph.D., Director of Georgia State University’s Office of Technology Transfer and Commercialization. “We were excited to partner with GeoVax on this project and are looking forward to seeing this technology continue to advance.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against multiple cancers. The Company has designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the Americas, Western Europe, Japan, and Australia; human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of two separate collaborative efforts to apply its innovative gene therapy approach toward a functional cure for HIV.

About Modified Vaccinia Ankara (MVA)

The creation of our MVA viral vectors described in our patent filings was made possible through contribution of materials and methods developed in the laboratory of Dr. Bernard Moss of the National Institute of Allergy and Infectious Diseases (NIAID), Laboratory of Viral Diseases (LVD).

StephenW

GeoVax收到了乙肝疫苗专利许可通知

美国东部时间2021年4月1日09:00 |资料来源：GeoVax，Inc.

    ...

治疗性疫苗将满足全球超过2.5亿的医疗需求

2021年4月1日，佐治亚州亚特兰大（GLOBE NEWSWIRE）-通过NewMediaWire-GeoVax Labs，Inc.（NasdaqCM：GOVX）（“ GeoVax”或“ Company”），一家开发人类免疫疗法和针对传染病的疫苗的生物技术公司癌症和癌症，今天宣布，美国专利商标局已发布专利申请号为16 / 305,305的许可通知，标题为“对乙型肝炎病毒产生免疫反应的组成和方法”。

支持专利申请的工作是通过GeoVax与佐治亚州立大学之间的合作完成的，该专利由公司和乔治亚州立大学研究基金会（GSURF）共同拥有。

GeoVax董事长兼首席执行官David Dodd表示：“对于治疗慢性HBV感染存在明显，关键且尚未满足的医疗需求，这种感染影响了全球超过2.5亿人。对于许多感染者来说，乙型肝炎已经成为一种长期的慢性感染，可以导致严重甚至威胁生命的健康问题，例如肝硬化或肝癌。存在多种疫苗可以预防HBV感染，但是它们无法帮助已经诊断出该病的患者。尽管可以用药物治疗慢性HBV，但这种治疗方法不能治愈95％的患者，只能抑制病毒的复制，从而迫使开始此类治疗的人在他们的余生中继续使用。

“尽管我们的公司重点和发展重点仍然是我们的COVID-19疫苗和癌症免疫疗法计划，但开发针对慢性乙型肝炎感染的治疗方法也引起了人们的关注，并且作为我们长期关注的一部分，正在考虑中。多德先生总结说：“这项专利津贴增加了我们不断增长的全资，共同拥有和有执照的知识产权产品组合，目前共有70多个已批准或正在申请的专利申请，分布在20个专利家族中。”

佐治亚州立大学技术转移办公室主任克利福德·迈克尔斯（Clifford Michaels）补充说：“该项目是学术研究人员和行业合作伙伴的综合专业知识和才能如何解决问题，创新和创造价值的一个很好的例子。”商业化。 “我们很高兴与GeoVax合作开展该项目，并期待看到该技术继续发展。”

关于GeoVax

GeoVax Labs，Inc.是一家临床阶段生物技术公司，它使用基于专利的新型改良牛痘安卡拉病毒样颗粒（MVA-VLP）疫苗平台开发针对传染病和癌症的人类疫苗。在这个平台上，MVA是一种能够携带多种疫苗抗原的大型病毒，它在接受疫苗的人中表达组装成VLP免疫原的蛋白质。疫苗接种者体内VLP的产生可模仿自然感染中的病毒产生，刺激免疫系统的体液和细胞臂以识别，预防和控制目标感染。衍生自MVA-VLP的疫苗可在宿主中引起类似于减毒活病毒的持久免疫反应，同时提供复制缺陷型载体的安全性。

GeoVax当前的开发计划专注于针对COVID-19，HIV，寨卡病毒，出血热病毒（埃博拉，苏丹，马尔堡和拉萨）和疟疾的预防性疫苗，以及针对多种癌症的治疗性疫苗。该公司设计了一种预防性HIV疫苗候选物，以对抗在美洲，西欧，日本和澳大利亚的商业市场中流行的亚型HIV； HIV疫苗试验网络（HVTN）在美国国立卫生研究院（NIH）的支持下，对该计划的人体临床试验进行管理。 GeoVax的HIV疫苗也是将其创新的基因疗法应用于HIV的功能性治疗的两项独立合作的一部分。

关于改良痘苗安卡拉（MVA）

通过在美国过敏和传染病研究所（NIAID）的伯纳德·莫斯（Bernard Moss）博士实验室，病毒性疾病（LVD）实验室开发的材料和方法的贡献，可以创建我们在专利文件中描述的MVA病毒载体。 。